-
Mashup Score: 2Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy - 26 day(s) ago
Patients with metastatic neuroendocrine tumors (NETs) can present with hundreds of lesions, and each lesion might have a unique response pattern to peptide receptor radiopharmaceutical therapy (PRRT). This response heterogeneity has been observed but is poorly understood. In this work, we perform a quantitative analysis of longitudinal PET/CT scans to comprehensively characterize the NET response to PRRT. Methods: NET patients treated with [177Lu]Lu-DOTATATE PRRT imaged at baseline, during, and after PRRT with [68Ga]Ga-DOTATATE PET/CT were enrolled in this retrospective single-institutional study. A deep-learning model was used to identify and contour regions of nonphysiological elevated tracer uptake (lesion-regions of interest [ROIs]). An automated analysis was performed to identify, contour, and quantify the individual lesion-ROI uptake, match ROI between time points, and categorize each lesion-ROI as disappearing, decreasing (ΔSUVtotal < −30%), stable (−30% ≤ ΔSUVtotal ≤ 30%), incr
Source: jnm.snmjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10
Given the heterogeneous clinical behavior of pancreatic neuroendocrine tumors (pNETs), improved prognostic markers are needed to guide management and post-resection surveillance. Patients who underwe…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma - 27 day(s) ago
Pancreatic neuroendocrine neoplasm (panNEN) is a rare malignancy and the second most common type of pancreatic cancer, after pancreatic ductal adenocarcinoma (PDAC), but its etiology is poorly understood. We investigated whether the risk factors of panNEN are concordant with those known for PDAC. We performed the largest case-control study to date on panNENs comprising 927 sporadic nonfunctional panNEN cases and 1807 frequency-matched controls using data from the Mayo Clinic Biospecimen Resource for Pancreas Research. We assessed associations for obesity, first-degree family history of pancreatic cancer, cigarette smoking, overall type II diabetes mellitus (T2DM), new-onset T2DM (<1 year before panNEN diagnosis), longstanding T2DM (≥5 years), alcohol intake, and aspirin use. Multivariable logistic regression was used to calculate odds ratios and 95% confidence intervals (CIs). Our results show that overall T2DM (OR=1.71, 95% CI: 1.37-2.14) and new-onset T2DM (OR=2.65, 95% CI: 1.92-3.69
Source: erc.bioscientifica.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 58
Gastroenteropancreatic neuroendocrine neoplasms(GEP NEN) exhibit substantial biological heterogeneity, impacting clinical management and outcomes. In 2019, the WHO introduced the neuroendocrine tumour(NET) grade 3 (G3) subgroup, characterized by Ki-67>20% and a well-differentiated morphology and poorly differentiated neuroendocrine carcinomas(NEC) (Ki-67>20%). Since this update, questions about the prognostic implications and best treatment strategies for NET G3 and NEC remain. Therefore we initiated a real-world retrospective observational cohort study, using data from 225 NEC and 58 NET G3 patients treated in Belgium. Analysis of patient and tumour characteristics and the effect of survival was conducted. Most frequent primary locations were pancreatic (32.9%) and colorectal (21.5%), and 71.8% was diagnosed with stage IV disease. Median overall survival(mOS) was higher in NET G3 (41.3 months(m)) compared to NEC (13.2m). Of those who underwent functional imaging, fluorodeoxyglucose-po
Source: erc.bioscientifica.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 122Hematology & Medical Oncology Practice Updates and Board Review 2025 | Mayo Clinic School of Continuous Professional Development | CME Course Conference - 1 month(s) ago
February 3 – 7, 2025 – The Ritz Carlton Maui – Kapalua, Hawaii This course offers Live (in-person) and Livestream (virtual) attendance options. The Mayo Clinic Hematology & Medical Oncology Practice Updates and Board Review course is designed to provide attendees with up-to-date, practical information and best practices that can be applied immediately into daily clinical
Source: ce.mayo.eduCategories: General Medicine News, Hem/OncsTweet-
Looking for a good summary on the management of GEJ/gastric adenocarcinoma? If so, @sonbol_bassam has this summary from the Mayo Clinic Board Review Course. The summary one needs in a busy clinic. If you are looking for a great review course here it is - https://t.co/ySXoI2hQKt https://t.co/bmDErAFiKe
-
-
Mashup Score: 116Hematology & Medical Oncology Practice Updates and Board Review 2025 | Mayo Clinic School of Continuous Professional Development | CME Course Conference - 1 month(s) ago
February 3 – 7, 2025 – The Ritz Carlton Maui – Kapalua, Hawaii This course offers Live (in-person) and Livestream (virtual) attendance options. The Mayo Clinic Hematology & Medical Oncology Practice Updates and Board Review course is designed to provide attendees with up-to-date, practical information and best practices that can be applied immediately into daily clinical
Source: ce.mayo.eduCategories: General Medicine News, Hem/OncsTweet-
Looking for a good summary on the management of GEJ/gastric adenocarcinoma? If so, @sonbol_bassam has this summary from the Mayo Clinic Board Review Course. The summary one needs in a busy clinic. If you are looking for a great review course here it is - https://t.co/ySXoI2hQKt https://t.co/bmDErAFiKe
-
-
Mashup Score: 48
Annals of Surgical Oncology – Grade 1/2 PanNETs are mostly managed similarly, typically without any adjunct treatment with the belief that their overall metastasis rate is low. In oncology…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11Venous Thromboembolism in Patients with Neuroendocrine Neoplasms: A Systematic Review of Incidence, Types, and Clinical Outcomes - 1 month(s) ago
Background: Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors with unique biological characteristics and complications, including thromboembolism. This systematic review evaluates the incidence, types, and clinical outcomes of venous thromboembolic events (VTEs) in NEN patients. Methods: A systematic search of PubMed, Scopus, and Embase was conducted to identify studies on TEs in NENs. Eligible studies included case reports, case series, and retrospective cohort studies reporting VTEs, including deep vein thrombosis (DVT), pulmonary embolism (PE), and visceral vein thrombosis (VVT). Data were extracted on tumor site, functionality, differentiation grade, and VTE type. Results: In total, 33 studies were included, comprising 26 case reports, 2 case series, and 5 retrospective cohort studies. VTE prevalence ranged from 7.5% to 33% across studies. The most common VTEs were DVT, PE, and portal vein thrombosis (PVT). A meta-analysis revealed a pooled VTE prevalence of 11.1%
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Therapy-Related Myeloid Tumors in Neuroendocrine Neoplasms After Peptide Receptor Radionuclide Therapy - 1 month(s) ago
This systematic review evaluates the literature and reports the incidence, time of diagnosis, and nature of therapy-related myeloid neoplasms after peptide receptor radionuclide therapy.
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet-
@AnnSurgOncol @JamesHoweV So far, alpha particle PRRT seems to be well tolerated. Still early on, hematologic toxicity needs to be better characterized. hematologic malignancies are certainly seen, the risk maybe 2-3% if no prior or subsequent chemo, possibly higher with chemo https://t.co/XnLXd5aSFU
-
-
Mashup Score: 066 million-year-old fossilised vomit discovered in Denmark - 1 month(s) ago
Experts say the discovery will help them understand what animals were eating during the Cretaceous period.
Source: www.bbc.comCategories: General Medicine News, Hem/OncsTweet
Response assessment following PRRT in patients with metastatic NETs. Not as simple as one might have thought... Response heterogeneity in all patients in this small study. https://t.co/bha3xNs98Y